Works matching IS 03407004 AND DT 2014 AND VI 63 AND IP 8
Results: 9
Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 835, doi. 10.1007/s00262-014-1557-4
- By:
- Publication type:
- Article
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 847, doi. 10.1007/s00262-014-1561-8
- By:
- Publication type:
- Article
Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 797, doi. 10.1007/s00262-014-1554-7
- By:
- Publication type:
- Article
Altered chemokine production and accumulation of regulatory T cells in intestinal adenomas of APC mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 807, doi. 10.1007/s00262-014-1555-6
- By:
- Publication type:
- Article
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 821, doi. 10.1007/s00262-014-1556-5
- By:
- Publication type:
- Article
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 779, doi. 10.1007/s00262-014-1551-x
- By:
- Publication type:
- Article
B7-H1 signaling is integrated during CD8 T cell priming and restrains effector differentiation.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 859, doi. 10.1007/s00262-014-1563-6
- By:
- Publication type:
- Article
Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 757, doi. 10.1007/s00262-014-1578-z
- By:
- Publication type:
- Article
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 787, doi. 10.1007/s00262-014-1547-6
- By:
- Publication type:
- Article